Published in J Gen Virol on October 01, 1982
Rotavirus gene structure and function. Microbiol Rev (1989) 6.95
Production and preliminary characterization of monoclonal antibodies directed at two surface proteins of rhesus rotavirus. J Virol (1983) 5.44
Direct isolation in cell culture of human rotaviruses and their characterization into four serotypes. J Clin Microbiol (1983) 4.88
Human viral gastroenteritis. Microbiol Rev (1984) 2.70
Synthesis and immunogenicity of the rotavirus major capsid antigen using a baculovirus expression system. J Virol (1987) 2.29
RNA-binding proteins of bovine rotavirus. J Virol (1986) 2.26
Response of mice to rotaviruses of bovine or primate origin assessed by radioimmunoassay, radioimmunoprecipitation, and plaque reduction neutralization. Infect Immun (1983) 2.06
Nucleotide sequence of the gene encoding the serotype-specific glycoprotein of UK bovine rotavirus. Nucleic Acids Res (1983) 1.65
Effects of tunicamycin on rotavirus morphogenesis and infectivity. J Virol (1983) 1.61
Passive protection against rotavirus-induced diarrhea by monoclonal antibodies to the heterotypic neutralization domain of VP7 and the VP8 fragment of VP4. J Clin Microbiol (1989) 1.58
Induction of cross-reactive serum neutralizing antibody to human rotavirus in calves after in utero administration of bovine rotavirus. J Clin Microbiol (1983) 1.49
Cloning and nucleotide sequence of the simian rotavirus gene 6 that codes for the major inner capsid protein. Nucleic Acids Res (1984) 1.48
Isolation and characterization of an equine rotavirus. J Clin Microbiol (1983) 1.07
Polypeptide composition of rotavirus empty capsids and their possible use as a subunit vaccine. J Virol (1990) 0.95
Nomenclature of human rotaviruses: designation of subgroups and serotypes. Bull World Health Organ (1984) 0.77
Molecular epidemiology of human rotavirus. J Hyg (Lond) (1986) 0.77
Membrane binding and endoplasmic reticulum retention sequences of rotavirus VP7 are distinct: role of carboxy-terminal and other residues in membrane binding. J Virol (1995) 0.77
Identification of the sequence responsible for the nuclear accumulation of the influenza virus nucleoprotein in Xenopus oocytes. Cell (1985) 3.36
Dependence of the activity of an influenza virus neuraminidase upon Ca2+. J Gen Virol (1971) 2.59
Differences between the thermal inactivation of picornaviruses at "high" and "low" temperatures. Virology (1967) 2.41
Mechanisms of neutralization of animal viruses. J Gen Virol (1984) 2.16
Review article initial stages in infection with animal viruses. J Gen Virol (1982) 1.87
Defective interfering viruses and infections of animals. Curr Top Microbiol Immunol (1986) 1.83
An electron microscopic study of single-cycle infection of chick embryo fibroblasts by influenza virus. Virology (1969) 1.65
New virus-specific antigens in cells infected with influenza virus. Virology (1969) 1.48
Effect of antibody to neuraminidase on the maturation and hemagglutinating activity of an influenza A2 virus. J Virol (1969) 1.47
Defective interfering viruses and their potential as antiviral agents. Rev Med Virol (2010) 1.44
Quantitative relationships between an influenza virus and neutralizing antibody. Virology (1987) 1.37
Neutralization of animal virus infectivity by antibody. Arch Virol (2007) 1.34
Mechanism of neutralization of influenza virus by secretory IgA is different from that of monomeric IgA or IgG. J Exp Med (1985) 1.29
Electrophoretic separation of influenza virus ribonucleoproteins. J Gen Virol (1981) 1.27
Neutralization escape mutants of type A influenza virus are readily selected by antisera from mice immunized with whole virus: a possible mechanism for antigenic drift. J Gen Virol (1994) 1.26
Mechanisms of neutralization of influenza virus on mouse tracheal epithelial cells by mouse monoclonal polymeric IgA and polyclonal IgM directed against the viral haemagglutinin. J Gen Virol (1990) 1.24
A human IgG1 (b12) specific for the CD4 binding site of HIV-1 neutralizes by inhibiting the virus fusion entry process, but b12 Fab neutralizes by inhibiting a postfusion event. Virology (1997) 1.24
Biophysical studies of a rhinovirus. Extraction and assay of infectious ribonucleic acid. Nature (1966) 1.19
Inhibition of synthesis of influenza virus proteins: evidence of two host-cell-dependent events during multiplication. Virology (1975) 1.19
Insights into neutralization of animal viruses gained from study of influenza virus. Epidemiol Infect (1991) 1.12
Polyadenylic acid sequences in rhinovirus RNA species from infected human diploid cells. J Virol (1975) 1.11
Prevention of death in Semliki Forest virus-infected mice by administration of defective-interfering Semliki Forest virus. J Gen Virol (1978) 1.09
The RNAs of defective-interfering influenza virus. Virology (1978) 1.09
Single- and multi-hit kinetics of immunoglobulin G neutralization of human immunodeficiency virus type 1 by monoclonal antibodies. J Gen Virol (1994) 1.08
Studies on the mechanism of neutralization of influenza virus by antibody: evidence that neutralizing antibody (anti-haemagglutinin) inactivates influenza virus in vivo by inhibiting virion transcriptase activity. J Gen Virol (1982) 1.07
Defective segment 1 RNAs that interfere with production of infectious influenza A virus require at least 150 nucleotides of 5' sequence: evidence from a plasmid-driven system. J Gen Virol (2002) 1.06
A haemagglutinin (HA1)-specific FAb neutralizes influenza A virus by inhibiting fusion activity. J Gen Virol (2001) 1.06
Variations in the neutralizing and haemagglutination-inhibiting activities of five influenza A virus-specific IgGs and their antibody fragments. J Gen Virol (1997) 1.05
The differentiation state of monocytic cells affects their susceptibility to infection and the effects of infection by dengue virus. J Gen Virol (1994) 1.04
Hemagglutinin 1-specific immunoglobulin G and Fab molecules mediate postattachment neutralization of influenza A virus by inhibition of an early fusion event. J Virol (2001) 1.04
Approximately 150 nucleotides from the 5' end of an influenza A segment 1 defective virion RNA are needed for genome stability during passage of defective virus in infected cells. Virology (2000) 1.03
Studies on antigenic variations of the haemagglutinin and neuraminidase of swine influenza virus isolates. J Gen Virol (1970) 1.02
Phosphorylation of influenza virus nucleoprotein in vivo. J Gen Virol (1981) 1.01
Failure of an influenza virus to initiate infection in enucleate BHK cells. J Virol (1974) 1.00
Human immunodeficiency virus type 1-neutralizing antibodies raised to a glycoprotein 41 peptide expressed on the surface of a plant virus. AIDS Res Hum Retroviruses (1995) 0.98
Morphological studies of the neutralization of influenza virus by IgM. J Gen Virol (1990) 0.98
Early events in influenza virus multiplication. II. Penetration of virus into cells at 4 degrees. Virology (1978) 0.97
Fowl plaque virus replication in mammalian cell-avian erythrocyte heterokaryons: studies concerning the actinomycin D and ultra-violet light sensitive phase in influenza virus replication. Virology (1974) 0.96
Summary of antibody workshop: The Role of Humoral Immunity in the Treatment and Prevention of Emerging and Extant Infectious Diseases. J Infect Dis (1997) 0.95
Protection of mice from lethal influenza by adoptive transfer of non-neutralizing haemagglutination-inhibiting IgG obtained from the lungs of infected animals treated with defective interfering virus. J Gen Virol (1989) 0.95
Semliki Forest virus infection of mice: a model for genetic and molecular analysis of viral pathogenicity. J Gen Virol (1985) 0.95
Two neutralizing anti-V3 monoclonal antibodies act by affecting different functions of human immunodeficiency virus type 1. J Gen Virol (1996) 0.94
Categorization of nucleoproteins and matrix proteins from type A influenza viruses by peptide mapping. Virology (1980) 0.94
Selection of neutralizing antibody escape mutants with type A influenza virus HA-specific polyclonal antisera: possible significance for antigenic drift. Epidemiol Infect (1997) 0.94
Replication of rhinovirus RNA. J Gen Virol (1973) 0.94
Interfering vaccine (defective interfering influenza A virus) protects ferrets from influenza, and allows them to develop solid immunity to reinfection. Vaccine (2006) 0.94
A single amino acid change in the E2 spike protein of a virulent strain of Semliki Forest virus attenuates pathogenicity. J Gen Virol (1994) 0.94
Common sequence elements in structurally unrelated genomes of defective interfering Semliki Forest virus. Virology (1994) 0.93
Location of influenza virus M, NP and NS1 proteins in microinjected cells. J Gen Virol (1985) 0.93
High and low efficiency neutralization epitopes on the haemagglutinin of type A influenza virus. J Gen Virol (1997) 0.93
Kinetics of synthesis of influenza virus ribonucleoprotein structures. J Gen Virol (1982) 0.92
Protection of mice from lethal influenza: evidence that defective interfering virus modulates the immune response and not virus multiplication. J Gen Virol (1986) 0.91
Temporal control of transcription of influenza virus RNA. Virology (1975) 0.90
Selective inhibition of influenza virus protein synthesis by inhibitors of DNA function. Virology (1977) 0.90
One defective interfering particle per cell prevents influenza virus-mediated cytopathology: an efficient assay system. J Gen Virol (1988) 0.90
Analysis of the ability of five adjuvants to enhance immune responses to a chimeric plant virus displaying an HIV-1 peptide. Vaccine (1999) 0.89
IgG neutralization of type A influenza viruses and the inhibition of the endosomal fusion stage of the infectious pathway in BHK cells. Virology (1993) 0.89
A monoclonal antibody produced during infection which recognizes an epitope of influenza hemagglutinin only in the context of H-2k MHC class I antigen. J Immunol (1993) 0.88
IgG-neutralized influenza virus undergoes primary, but not secondary uncoating in vivo. J Gen Virol (1989) 0.88
A rapid method for the inactivation of virus infectivity prior to assay for interferons. J Virol Methods (1984) 0.88
Defective interfering particles of Semliki Forest virus are smaller than particles of standard virus. J Gen Virol (1984) 0.87
All rabbits immunized with type A influenza virions have a serum haemagglutination-inhibition antibody response biased to a single epitope in antigenic site B. J Gen Virol (1995) 0.86
Mechanisms of neutralization of influenza virus by IgM. J Gen Virol (1985) 0.86
Properties of a neutralizing antibody that recognizes a conformational form of epitope ERDRD in the gp41 C-terminal tail of human immunodeficiency virus type 1. J Gen Virol (2000) 0.86
Rhinovirus RNA polymerase: products and kinetics of appearance in human diploid cells. J Virol (1974) 0.85
Intranasal immunization with a plant virus expressing a peptide from HIV-1 gp41 stimulates better mucosal and systemic HIV-1-specific IgA and IgG than oral immunization. J Immunol Methods (1998) 0.85
Determination of affinities of a panel of IgGs and Fabs for whole enveloped (influenza A) virions using surface plasmon resonance. J Virol Methods (1996) 0.85
Different patterns of polyadenylation of rhinovirus: specified RNA during multiplication in human aneuploid and diploid cells. J Gen Virol (1976) 0.85
RNA'S of influenza C virus strains. Arch Virol (1979) 0.84
The effect of defective-interfering Semliki Forest virus on the histopathology of infection with virulent Semliki Forest virus in mice. J Infect Dis (1982) 0.84
The neutralizing antibody response against a conserved region of human immunodeficiency virus type 1 gp41 (amino acid residues 731-752) is uniquely directed against a conformational epitope. J Gen Virol (1998) 0.84
Defective interfering type A equine influenza virus (H3N8) protects mice from morbidity and mortality caused by homologous and heterologous subtypes of influenza A virus. J Gen Virol (1994) 0.83
Early events in influenza virus infection. III. The formation of a nucleoplasmic ribonucleoprotein complex from the input virion. Virology (1978) 0.83
Protection of three strains of mice against lethal influenza in vivo by defective interfering virus. Virus Res (1993) 0.83
Intracellular stability of the interfering activity of a defective interfering influenza virus in the absence of virus multiplication. Virology (1987) 0.83
A preliminary study of physiological characteristics of temperature-sensitive mutants of influenza virus. J Gen Virol (1973) 0.83
Defective interfering influenza virus inhibits immunopathological effects of infectious virus in the mouse. J Virol (1992) 0.82
Subclinical infections in mice resulting from the modulation of a lethal dose of Semliki Forest virus with defective interfering viruses: neurochemical abnormalities in the central nervous system. J Gen Virol (1986) 0.82
Postattachment neutralization of a primary strain of HIV type 1 in peripheral blood mononuclear cells is mediated by CD4-specific antibodies but not by a glycoprotein 120-specific antibody that gives potent standard neutralization. AIDS Res Hum Retroviruses (2001) 0.82
Early events in influenza virus multiplication. I. Location and fate of the input RNA. Virology (1975) 0.82
Persistence of virulent Semliki Forest virus in mouse brain following co-inoculation with defective interfering particles. J Gen Virol (1986) 0.82
Longitudinal study of an epitope-biased serum haemagglutination-inhibition antibody response in rabbits immunized with type A influenza virions. Vaccine (1996) 0.81
The genomic sequence of defective interfering Semliki Forest virus (SFV) determines its ability to be replicated in mouse brain and to protect against a lethal SFV infection in vivo. Virology (1998) 0.81
Inhibition of the processing of ribosomal RNA in avian cells infected with an influenza virus. Biochim Biophys Acta (1974) 0.81
Polymorphism of the NS1 proteins of type A influenza virus. J Gen Virol (1982) 0.81
Virulent and avirulent strains of Semliki Forest virus show similar cell tropism for the murine central nervous system but differ in the severity and rate of induction of cytolytic damage. Neuropathol Appl Neurobiol (1993) 0.81
Heterogeneity of apparently empty poliovirus particles stained with phosphotungstic acid after heating of the virus at "low" temperature. Virology (1967) 0.81
Assay of defective-interfering semliki forest virus by the inhibition of synthesis of virus-specified RNAs. J Gen Virol (1981) 0.81
Defective influenza A virus generated entirely from plasmids: its RNA is expressed in infected mouse lung and modulates disease. J Virol Methods (2003) 0.81
Modulation of Semliki Forest virus-induced infection of mice by defective-interfering virus. J Infect Dis (1984) 0.80
Modulation of a systemic Semliki Forest virus infection in mice by defective interfering virus. J Gen Virol (1984) 0.80